Literature DB >> 2530547

[Comparative study of 2 dosage regimens of cefixime in the treatment of otorhinolaryngeal or bronchial infections].

O Boudignat1, R Zylbertrest, G Roche.   

Abstract

A double-blind comparative study of cefixime (400 mg/day), given either as a single daily dose, or in two divided doses, was carried out in collaboration with 54 general practitioners. This study was mainly directed towards tolerance assessment. 431 patients with upper and lower respiratory tract infection were included. In terms of tolerance, 89 per cent of patients showed no side-effect and the tolerance was deemed satisfactory in 90.3 per cent of the cases by the investigators, without any statistically significant difference between both groups. Roughly, the most frequent side-effects were gastrointestinal reactions, such as diarrhea or stool changes (4.0 per cent), gastralgia (1.9 per cent), nausea and/or vomiting (1.6 per cent). In terms of effectiveness, after an average of 8.8 +/- 0.1 days of treatment, 94.4 per cent of assessable patients were improved or cured. Once again, there was no statistical difference between both groups. Cefixime effectiveness and safety are comparable with both modes of administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2530547

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  6 in total

1.  [Cefixime therapy in sinusitis].

Authors:  W Jorde; M Schata
Journal:  Infection       Date:  1990       Impact factor: 3.553

2.  [Cefixime treatment in different bacterial infections in the ENT region].

Authors:  W W Schlenter; R Blessing; K Pelz; U Benner
Journal:  Infection       Date:  1990       Impact factor: 3.553

3.  [Effectiveness and tolerance of cefixime in bacterial infections in the ENT area].

Authors:  M Theopold; U Benner; A Bauernfeind
Journal:  Infection       Date:  1990       Impact factor: 3.553

4.  Clinical efficacy and tolerability of cefixime in the treatment of acute sinusitis.

Authors:  P Gehanno; I Boucot; P Berche; J Uhlrich
Journal:  Drugs       Date:  1991       Impact factor: 9.546

5.  Safety and efficacy of cefixime in treatment of respiratory tract infections in Germany.

Authors:  T Hausen; G Weidlich; J Schmitt
Journal:  Infection       Date:  1995       Impact factor: 3.553

6.  Efficacy and Tolerability of 5- vs 10-Day Cefixime Therapy in Acute Exacerbations of Chronic Bronchitis.

Authors:  J Lorenz; P Steinfeld; L Drath; T Keienburg; K Troester
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.